Neurogene Inc. (NGNE) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Neurogene Inc. (NGNE) closed at USD 22.18 on 2026-10-14, a change of -28.5 % over the past year, with a market capitalization of USD 479.27M.

Neurogene Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Neurogene Inc. key figures

Previous close

USD 22.18 (2026-10-14)

1-year change

-28.5 %

Market cap

USD 479.27M

Enterprise value

USD 262.23M

P/E ratio (trailing)

-4.63

P/E ratio (forward)

-4.18

EPS (trailing)

-5.17

EPS (forward)

-5.72

PEG ratio

n/a

Price to book

1.75

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

16.10

Employees

131

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Neurogene Inc.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Neurogene Inc. and compare it with other stocks.